Suministros de Nivolumab (DOE), Ipilimumab (DOE), Fedratinib (DOE), Luspatercept (DOE), Azacitidina (DOE) y Abatacept (DOE)
Deadline:N/A
Contract award
Estimated value
€56,530,520.58
Duration
5 years
Bidders
Awarded bidders
Name
BRISTOL-MYERS SQUIBB, S.A.